Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Skyline Therapeutics Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by a distinct examiner in a distinct art unit. The prosecution activity is currently limited to this case within the patent office, reflecting a concentrated effort on a specific technology. This action is the only active matter for the company at this time. The focus on Biotechnology & Pharmaceuticals indicates a strategic interest in advanced therapeutic developments.
Hashanthi Komitige Abeyratne-Perera is the busiest examiner for the portfolio, managing 1 pending office action. This action constitutes the entire pending workload for the company, making the review process with Hashanthi Komitige Abeyratne-Perera the sole focus of their current patent office communications. Practitioners should prioritize the feedback from the examiner, as she is the only individual currently reviewing the company's applications. The resolution of this case will be the primary determinant of the company's patent standing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725000 | RECOMBINANT AAV FOR THE GENE THERAPY OF FABRY DISEASE | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725000 | RECOMBINANT AAV FOR THE GENE THERAPY OF FABRY DISEASE | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §112 | Non-Final OA | — | Pending | Jun 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSkyline Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hashanthi Komitige Abeyratne-Perera has the most, with 1 of Skyline Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
